Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (<scp>HASTE</scp>): How to meet major health needs at a reasonable cost

Enrico Costa(Brigham and Women's Hospital), Lucio Luzzatto(University of Florence), Prosper Tibalinda(Muhimbili University of Health and Allied Sciences), Enrico Sterzi(Azienda Ospedaliera Universitaria Integrata Verona), Julie Makani(Muhimbili University of Health and Allied Sciences), Eliangiringa Kaale(Muhimbili University of Health and Allied Sciences), H Leufkens(Pharmo Institute)
American Journal of Hematology
September 25, 2020
10.1002/ajh.26007
Cited by 31

Related Papers

The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Natural History of Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|1995|900
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
|Blood|2007|578
The Lancet NCDI Poverty Commission: bridging a gap in universal health coverage for the poorest billion
|The Lancet|2020|298
Isolation of human glucose-6-pbosphate debydrogenase (G6PD) cDNA clones: primary structure of the protein and unusual 5' non-coding region
|Nucleic Acids Research|1986|246